Imatinib Viatris

Imatinib, the active ingredient in Imatinib Viatris, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor, and dermatofibrosarcoma protuberans in appropriate patients.

GNH USA supplies Imatinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network adheres to stringent quality standards and ensures timely delivery across multiple regions, including Europe, Asia and the Americas.

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid tumor indications that involve BCR‑ABL, KIT or PDGFR signaling. - Chronic myeloid leukemia (CML): controls disease progression by targeting BCR‑ABL kinase. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by inhibiting BCR‑ABL driven proliferation. - Gastrointestinal stromal tumor (GIST): reduces tumor growth by blocking KIT signaling. - Dermatofibrosarcoma protuberans (DFSP): induces tumor regression through PDGFR inhibition.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: fluid retention, often peripheral. - Fatigue: generalized tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: congestive heart failure or reduced left‑ventricular function. - Severe neutropenia: marked decrease in neutrophil count increasing infection risk.

When prescribing Imatinib, clinicians should consider several precautionary measures to minimize risk and ensure safe use. - Baseline assessment: obtain complete blood count, liver function tests and renal function before initiating therapy. - Monitoring: perform regular CBC and hepatic panels during treatment to detect cytopenias or liver toxicity. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers that may alter exposure. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Imatinib interacts with several agents that can affect its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Imatinib levels, risking toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Imatinib exposure, reducing efficacy.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: can reduce absorption; separate dosing by at least 2 hours. - Proton pump inhibitors: may modestly decrease bioavailability; monitor therapeutic response. - Concomitant cardiotoxic drugs (e.g., anthracyclines): increase risk of cardiac dysfunction; observe cardiac function.